pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 4·1 min read
save

Two drugmakers petition Supreme Court to reinstate mail-order access to abortion pill mifepristone

May 4, 2026·read at STAT ↗RegulatoryNeutral

Two drugmakers, Danco Laboratories and GenBioPro, have asked the U.S. Supreme Court to restore mail-order distribution of mifepristone, the abortion pill.

The request follows a recent appellate court ruling that halted mail-order shipments, raising concerns about continued access for women seeking medication abortions.

If granted, the petition would allow the existing mail-order system to remain in place while broader legal challenges to the drug continue, according to Reuters.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news”

read at STAT ↗
675 words · retrieved May 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA2
drugs
MIFEPRISTONE4Obesity
topics
Obesity2ApprovalImmunology

related stories

  • Sep 29STAT+: AstraZeneca invests $2 billion in Summit TherapeuticsSTAT
  • Sep 4This week in charts: China deals, stock flatlines and Lilly’s M&A spreeBioPharma Dive
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Aug 27New data could widen use of AstraZeneca, Amgen immune disease drugBioPharma Dive
  • Aug 20Chutes & Ladders—Neumora shuffles leadership ahead of INDFierce Biotech